These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 29473149)

  • 1. CYP2D6 and Endoxifen in Tamoxifen Therapy: A Tribute to David A. Flockhart.
    Skaar TC; Desta Z
    Clin Pharmacol Ther; 2018 May; 103(5):755-757. PubMed ID: 29473149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.
    Goetz MP; Sangkuhl K; Guchelaar HJ; Schwab M; Province M; Whirl-Carrillo M; Symmans WF; McLeod HL; Ratain MJ; Zembutsu H; Gaedigk A; van Schaik RH; Ingle JN; Caudle KE; Klein TE
    Clin Pharmacol Ther; 2018 May; 103(5):770-777. PubMed ID: 29385237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects.
    Dezentjé VO; Opdam FL; Gelderblom H; Hartigh den J; Van der Straaten T; Vree R; Maartense E; Smorenburg CH; Putter H; Dieudonné AS; Neven P; Van de Velde CJ; Nortier JW; Guchelaar HJ
    Breast Cancer Res Treat; 2015 Oct; 153(3):583-90. PubMed ID: 26369533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.
    Hertz DL; Deal A; Ibrahim JG; Walko CM; Weck KE; Anderson S; Magrinat G; Olajide O; Moore S; Raab R; Carrizosa DR; Corso S; Schwartz G; Graham M; Peppercorn JM; Jones DR; Desta Z; Flockhart DA; Evans JP; McLeod HL; Carey LA; Irvin WJ
    Oncologist; 2016 Jul; 21(7):795-803. PubMed ID: 27226358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics and pharmacokinetics of tamoxifen in a Zimbabwean breast cancer cohort.
    Mbavha BT; Thelingwani RS; Chikwambi Z; Nyakabau AM; Masimirembwa C;
    Br J Clin Pharmacol; 2023 Oct; 89(10):3209-3216. PubMed ID: 37337448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study.
    Sanchez-Spitman A; Dezentjé V; Swen J; Moes DJAR; Böhringer S; Batman E; van Druten E; Smorenburg C; van Bochove A; Zeillemaker A; Jongen L; Los M; Neven P; Gelderblom H; Guchelaar HJ
    J Clin Oncol; 2019 Mar; 37(8):636-646. PubMed ID: 30676859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.
    Ruddy KJ; Desantis SD; Gelman RS; Wu AH; Punglia RS; Mayer EL; Tolaney SM; Winer EP; Partridge AH; Burstein HJ
    Breast Cancer Res Treat; 2013 Oct; 141(3):421-7. PubMed ID: 24062210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Drug Monitoring of endoxifen as an alternative for CYP2D6 genotyping in individualizing tamoxifen therapy.
    de Vries Schultink AHM; Huitema ADR; Beijnen JH
    Breast; 2018 Dec; 42():38-40. PubMed ID: 30153552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.
    Borges S; Desta Z; Li L; Skaar TC; Ward BA; Nguyen A; Jin Y; Storniolo AM; Nikoloff DM; Wu L; Hillman G; Hayes DF; Stearns V; Flockhart DA
    Clin Pharmacol Ther; 2006 Jul; 80(1):61-74. PubMed ID: 16815318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of rs5758550 on CYP2D6*2 phenotype and formation of endoxifen in breast cancer patients using tamoxifen.
    Sanchez-Spitman AB; Moes DA; Gelderblom H; Dezentjé VO; Swen JJ; Guchelaar HJ
    Pharmacogenomics; 2017 Aug; 18(12):1125-1132. PubMed ID: 28745555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function CYP2D6 alleles.
    Thorén L; Lindh JD; Ackehed G; Kringen MK; Hall P; Bergh J; Molden E; Margolin S; Eliasson E
    Br J Clin Pharmacol; 2021 Mar; 87(3):1243-1252. PubMed ID: 32713032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)-Endoxifen in Breast Cancer.
    Nardin JM; Schroth W; Almeida TA; Mürdter T; Picolotto S; Vendramini ECL; Hoppe R; Kogin JP; Miqueleto D; de Moraes SDR; Schwab M; Pecoits-Filho RF; Brauch H; Casali-da-Rocha JC
    Clin Transl Sci; 2020 Mar; 13(2):284-292. PubMed ID: 31573754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio.
    Lee CI; Low SK; Maldonado R; Fox P; Balakrishnar B; Coulter S; de Bruijn P; Koolen SLW; Gao B; Lynch J; Zdenkowski N; Hui R; Liddle C; Mathijssen RHJ; Wilcken N; Wong M; Gurney H
    Breast; 2020 Dec; 54():229-234. PubMed ID: 33161337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment.
    de Graan AJ; Teunissen SF; de Vos FY; Loos WJ; van Schaik RH; de Jongh FE; de Vos AI; van Alphen RJ; van der Holt B; Verweij J; Seynaeve C; Beijnen JH; Mathijssen RH
    J Clin Oncol; 2011 Aug; 29(24):3240-6. PubMed ID: 21768449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen.
    Sanchez-Spitman AB; Swen JJ; Dezentje VO; Moes DJAR; Gelderblom H; Guchelaar HJ
    Expert Rev Clin Pharmacol; 2019 Jun; 12(6):523-536. PubMed ID: 31008668
    [No Abstract]   [Full Text] [Related]  

  • 16. The ethics of CYP2D6 testing for patients considering tamoxifen.
    Hartman AR; Helft P
    Breast Cancer Res; 2007; 9(2):103. PubMed ID: 17433116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.
    Ahern TP; Hertz DL; Damkier P; Ejlertsen B; Hamilton-Dutoit SJ; Rae JM; Regan MM; Thompson AM; Lash TL; Cronin-Fenton DP
    Am J Epidemiol; 2017 Jan; 185(2):75-85. PubMed ID: 27988492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
    Fleeman N; Martin Saborido C; Payne K; Boland A; Dickson R; Dundar Y; Fernández Santander A; Howell S; Newman W; Oyee J; Walley T
    Health Technol Assess; 2011 Sep; 15(33):1-102. PubMed ID: 21906462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2D6 and tamoxifen: DNA matters in breast cancer.
    Hoskins JM; Carey LA; McLeod HL
    Nat Rev Cancer; 2009 Aug; 9(8):576-86. PubMed ID: 19629072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Don't think twice it's all right: tamoxifen and CYP2D6 genotyping in the treatment of breast cancer patients.
    Damkier P
    Pharmacogenomics; 2017 Jun; 18(8):753-754. PubMed ID: 28592184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.